Marker Therapeutics, Inc. (MRKR)Healthcare | Biotechnology | Houston, United States | NasdaqCM
1.46 USD
-0.05
(-3.311%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 1.41 -0.05 (-0.055%) ⇩ (July 13, 2026, 7:21 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 5:08 a.m. EDT
The immediate outlook is flat due to a lack of directional catalysts, though the stock recently staged a modest bounce off its lows. However, the long-term picture is severely compromised by a decade-long structural decline where the share price has lost over 97% of its value, driven by six consecutive years of negative annual performance. While analysts project a significant recovery to the $8 range, the underlying reality is stark: the company is burning cash rapidly with negative gross margins and no path to profitability, leaving it exposed to the high risks typical of biotech ventures without the safety net of a dividend or stable earnings. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.033673 |
| AutoETS | 0.033704 |
| AutoARIMA | 0.033705 |
| MSTL | 0.035504 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 2.09 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.937 |
| Excess Kurtosis | -0.13 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.204 |
| Market Cap | 24,342,766 |
| Forward P/E | -1.93 |
| Beta | 1.45 |
| Website | https://markertherapeutics.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.044303775 |
| Address1 | 2,450 Holcombe Blvd |
| Address2 | TMC Partners Office 1.311 |
| All Time High | 6,120,000.0 |
| All Time Low | 0.67 |
| Ask | 1.86 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 93,640 |
| Average Daily Volume3 Month | 72,283 |
| Average Volume | 72,283 |
| Average Volume10Days | 93,640 |
| Beta | 1.454 |
| Bid | 1.06 |
| Bid Size | 2 |
| Book Value | 0.827 |
| City | Houston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.46 |
| Current Ratio | 4.792 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.53 |
| Day Low | 1.45 |
| Display Name | Marker Therapeutics |
| Dividend Date | 1,473,984,000 |
| Earnings Timestamp End | 1,755,518,400 |
| Earnings Timestamp Start | 1,754,996,340 |
| Ebitda Margins | 0.0 |
| Enterprise To Revenue | 2.658 |
| Enterprise Value | 9,427,246 |
| Eps Current Year | -0.69 |
| Eps Forward | -0.755 |
| Eps Trailing Twelve Months | -0.55 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.442 |
| Fifty Day Average Change | 0.018000007 |
| Fifty Day Average Change Percent | 0.012482667 |
| Fifty Two Week Change Percent | -4.4303775 |
| Fifty Two Week High | 4.07 |
| Fifty Two Week High Change | -2.6100001 |
| Fifty Two Week High Change Percent | -0.6412777 |
| Fifty Two Week Low | 0.81 |
| Fifty Two Week Low Change | 0.65000004 |
| Fifty Two Week Low Change Percent | 0.8024692 |
| Fifty Two Week Range | 0.81 - 4.07 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,026,826,200,000 |
| Float Shares | 13,809,684 |
| Forward Eps | -0.755 |
| Forward P E | -1.933775 |
| Free Cashflow | -5,248,198 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 5 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -2.2443 |
| Gross Profits | -7,959,786 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.05493 |
| Held Percent Institutions | 0.23396 |
| Implied Shares Outstanding | 16,673,127 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,674,777,600 |
| Last Split Factor | 1:10 |
| Long Business Summary | Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas. |
| Long Name | Marker Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 24,342,766 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_1725474 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -10,896,714 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 25,176,421 |
| Number Of Analyst Opinions | 3 |
| Open | 1.51 |
| Operating Cashflow | -7,918,536 |
| Operating Margins | -3.3849201 |
| Payout Ratio | 0.0 |
| Phone | 713 400 6400 |
| Post Market Change | -0.054700017 |
| Post Market Change Percent | -3.7465763 |
| Post Market Price | 1.4053 |
| Post Market Time | 1,783,984,889 |
| Previous Close | 1.51 |
| Price Eps Current Year | -2.115942 |
| Price Hint | 4 |
| Price To Book | 1.7654172 |
| Price To Sales Trailing12 Months | 6.8635573 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.478 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.05 |
| Regular Market Change Percent | -3.31126 |
| Regular Market Day High | 1.53 |
| Regular Market Day Low | 1.45 |
| Regular Market Day Range | 1.45 - 1.53 |
| Regular Market Open | 1.51 |
| Regular Market Previous Close | 1.51 |
| Regular Market Price | 1.46 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 34,634 |
| Return On Assets | -0.43589002 |
| Return On Equity | -0.77042 |
| Revenue Per Share | 0.204 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 16,673,127 |
| Shares Percent Shares Out | 0.0069999998 |
| Shares Short | 116,653 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 204,416 |
| Short Name | Marker Therapeutics, Inc. |
| Short Percent Of Float | 0.0086 |
| Short Ratio | 1.99 |
| Source Interval | 15 |
| State | TX |
| Symbol | MRKR |
| Target High Price | 10.0 |
| Target Low Price | 5.6 |
| Target Mean Price | 7.86667 |
| Target Median Price | 8.0 |
| Total Cash | 14,915,519 |
| Total Cash Per Share | 0.895 |
| Total Debt | 0 |
| Total Revenue | 3,546,669 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.55 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.37905 |
| Two Hundred Day Average Change | 0.08095002 |
| Two Hundred Day Average Change Percent | 0.058699846 |
| Type Disp | Equity |
| Volume | 34,634 |
| Website | https://markertherapeutics.com |
| Zip | 77,021 |